• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型氟喹诺酮类药物鲁氟沙星(MF 934)对革兰氏阴性菌和革兰氏阳性菌临床分离株的比较活性

Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.

作者信息

Qadri S M, Ueno Y, Postle G, Tullo D, San Pedro J

机构信息

Department of Pathology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

出版信息

Eur J Clin Microbiol Infect Dis. 1993 May;12(5):372-7. doi: 10.1007/BF01964437.

DOI:10.1007/BF01964437
PMID:8394816
Abstract

The antibacterial activity of the new fluoroquinolone rufloxacin (MF 934) was evaluated against 1095 clinical isolates and compared with that of other quinolones and various commonly used antibiotics. Rufloxacin was highly effective against members of the Enterobacteriaceae, inhibiting 98% of the isolates at a concentration of 1 mg/l. Ninety-two percent of Aeromonas hydrophila and 65% Acinetobacter strains tested were inhibited by 1 mg/l of rufloxacin, whereas 98% of methicillin-susceptible and 87% of methicillin-resistant Staphylococcus aureus strains and 76% of coagulase-negative staphylococci strains required 4 mg/l for growth inhibition. The MIC values of rufloxacin for most bacteria were 4-16 times higher than those of ciprofloxacin and norfloxacin. Rufloxacin had little activity against xanthomonads, pseudomonads and enterococci. Approximately 95-96% of isolates of Pseudomonas aeruginosa were inhibited by 2 mg/l of ciprofloxacin and norfloxacin as compared to 29% inhibited by rufloxacin at this concentration.

摘要

对新型氟喹诺酮类药物鲁氟沙星(MF 934)的抗菌活性进行了评估,以1095株临床分离菌为研究对象,并与其他喹诺酮类药物及各种常用抗生素进行比较。鲁氟沙星对肠杆菌科细菌具有高效抗菌活性,在浓度为1mg/l时可抑制98%的分离菌。1mg/l的鲁氟沙星可抑制92%的嗜水气单胞菌和65%的不动杆菌菌株,而对于甲氧西林敏感的金黄色葡萄球菌菌株,98%以及甲氧西林耐药的金黄色葡萄球菌菌株87%,还有76%的凝固酶阴性葡萄球菌菌株,需要4mg/l的浓度才能抑制其生长。鲁氟沙星对大多数细菌的最低抑菌浓度(MIC)值比环丙沙星和诺氟沙星高4至16倍。鲁氟沙星对黄单胞菌、假单胞菌和肠球菌几乎没有活性。浓度为2mg/l时,环丙沙星和诺氟沙星可抑制约95% - 96%的铜绿假单胞菌分离菌,而在此浓度下鲁氟沙星只能抑制29%的该菌分离菌。

相似文献

1
Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.新型氟喹诺酮类药物鲁氟沙星(MF 934)对革兰氏阴性菌和革兰氏阳性菌临床分离株的比较活性
Eur J Clin Microbiol Infect Dis. 1993 May;12(5):372-7. doi: 10.1007/BF01964437.
2
Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.曲伐沙星对医院内革兰氏阳性和革兰氏阴性分离株的抗菌活性。
J Antimicrob Chemother. 1997 Jun;39 Suppl B:29-34. doi: 10.1093/jac/39.suppl_2.29.
3
In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.曲伐沙星及其他五种氟喹诺酮类药物的体外抗菌活性
Chemotherapy. 1998 Mar-Apr;44(2):85-93. doi: 10.1159/000007097.
4
In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates.新型喹诺酮类药物鲁氟沙星对医院分离株的体外活性
Chemotherapy. 1991;37(4):260-9. doi: 10.1159/000238865.
5
Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia.
Chemotherapy. 1992;38(2):92-8. doi: 10.1159/000238947.
6
In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials.
Chemotherapy. 1991;37(3):166-74. doi: 10.1159/000238850.
7
In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
Chemotherapy. 1992;38(2):99-106. doi: 10.1159/000238948.
8
The in-vitro activity of two new quinolones: rufloxacin and MF 961.两种新型喹诺酮类药物:芦氟沙星和MF 961的体外活性
J Antimicrob Chemother. 1992 Jun;29(6):649-60. doi: 10.1093/jac/29.6.649.
9
Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
J Antimicrob Chemother. 1993 Jun;31(6):855-63. doi: 10.1093/jac/31.6.855.
10
Comparative in vitro activity of sparfloxacin (AT 4140, RP 64206--SPFX) against 275 multiresistant clinical isolates.
J Chemother. 1992 Feb;4(1):12-5. doi: 10.1080/1120009x.1992.11739131.

引用本文的文献

1
Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus.用于发现抗多重耐药金黄色葡萄球菌药物的全动物自动化平台。
PLoS One. 2014 Feb 19;9(2):e89189. doi: 10.1371/journal.pone.0089189. eCollection 2014.

本文引用的文献

1
Summary report of worldwide antibiotic resistance: international task forces on antibiotic use.全球抗生素耐药性总结报告:抗生素使用国际特别工作组
Rev Infect Dis. 1985 Jul-Aug;7(4):560-4. doi: 10.1093/clinids/7.4.560.
2
Changing pattern of resistant Shiga bacillus (Shigella dysenteriae type 1) and Shigella flexneri in Bangladesh.孟加拉国志贺氏杆菌(1型痢疾志贺氏菌)和福氏志贺氏菌耐药模式的变化
J Infect Dis. 1985 Dec;152(6):1114-9. doi: 10.1093/infdis/152.6.1114.
3
Increasing resistance to trimethoprim-sulfamethoxazole among isolates of Escherichia coli in developing countries.
发展中国家大肠埃希菌分离株对甲氧苄啶-磺胺甲恶唑的耐药性不断增加。
J Infect Dis. 1985 Dec;152(6):1107-13. doi: 10.1093/infdis/152.6.1107.
4
Antibiotic resistance in developing countries.
J Infect Dis. 1985 Dec;152(6):1103-6. doi: 10.1093/infdis/152.6.1103.
5
Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.喹诺酮羧酸。2. 7-氧代-2,3-二氢-7H-吡啶并[1,2,3-de][1,4]苯并噻嗪-6-羧酸的合成与抗菌活性评价
J Med Chem. 1987 Mar;30(3):465-73. doi: 10.1021/jm00386a005.
6
Differences in antimicrobial susceptibilities of clinical isolates in Saudi Arabia and the United States.沙特阿拉伯和美国临床分离株抗菌药敏性的差异。
J Natl Med Assoc. 1987 Apr;79(4):433-7.
7
A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics.一种新型三环氟喹诺酮类药物鲁氟沙星(MF - 934),具有引人关注的抗菌及药代动力学特性。
Drugs Exp Clin Res. 1988;14(12):747-54.
8
Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.芦氟沙星(MF - 934):体内外抗菌活性
Drugs Exp Clin Res. 1989;15(1):11-5.
9
Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.健康志愿者单次口服芦氟沙星后的药代动力学的个体间和个体内变异性。
Antimicrob Agents Chemother. 1991 Feb;35(2):390-3. doi: 10.1128/AAC.35.2.390.
10
Rufloxacin once daily in acute exacerbations of chronic bronchitis.慢性支气管炎急性加重期每日一次服用芦氟沙星。
Infection. 1991 Jul-Aug;19(4):297-300. doi: 10.1007/BF01644971.